Modality
mRNA
MOA
CAR-T CD19
Target
C5
Pathway
Complement
EoE
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
~Apr 2018
→ ~Jul 2019
Phase 3
~Oct 2019
→ ~Jan 2021
NDA/BLA
Apr 2021
→ Mar 2026
NDA/BLACurrent
NCT08551907
2,890 pts·EoE
2021-04→2026-03·Terminated
NCT07413112
2,136 pts·EoE
2025-01→2025-01·Terminated
5,026 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-01-151.2y agoPh3 Readout· EoE
2025-12-163mo agoBTD· EoE
2026-03-231w agoPh3 Readout· EoE
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
NDA/BLA
Termina…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2025-01-15 · 1.2y ago
EoE
BTD
2025-12-16 · 3mo ago
EoE
Ph3 Readout
2026-03-23 · 1w ago
EoE
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08551907 | NDA/BLA | EoE | Terminated | 2890 | EASI-75 |
| NCT07413112 | NDA/BLA | EoE | Terminated | 2136 | EFS |
Competitors (10)